Inspiration meets innovation at Brandweek, the ultimate marketing experience. Join industry luminaries, rising talent and strategic experts in Phoenix, Arizona this September 23–26 to assess challenges, develop solutions and create new pathways for growth. Register early to save.
Four global shops are vying to handle ad duties outside the U.S. for a new urinary-incontinence drug from Eli Lilly & Co. and Boehringer Ingelheim, sources said. The finalists for the estimated $25 million account are WPP’s J. Walter Thompson, London; Omnicom’s BBDO, Dusseldorf, Germany; Interpublic’s Foote, Cone & Belding, New York; and Havas’ Euro RSCG Life, London, sources said. Final pitches are scheduled for mid-October at Boehringer Ingelheim’s headquarters in Ingelheim, Germany, said sources.
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in